Potential predictors of immunotherapy in small cell lung cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F23%3AE0110284" target="_blank" >RIV/00843989:_____/23:E0110284 - isvavai.cz</a>

Result on the web

<a href="https://www.por-journal.com/articles/10.3389/pore.2023.1611086/full" target="_blank" >https://www.por-journal.com/articles/10.3389/pore.2023.1611086/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/pore.2023.1611086" target="_blank" >10.3389/pore.2023.1611086</a>

Result language

angličtina

Original language name

Potential predictors of immunotherapy in small cell lung cancer

Original language description

Lung cancer is one of the leading causes of cancer-related deaths worldwide, with small cell lung cancer (SCLC) having the worst prognosis. SCLC is diagnosed late in the disease's progression, limiting treatment options. The most common treatment for SCLC is chemotherapy. As the disease progresses, immunotherapy, most commonly checkpoint inhibitor medication, becomes more important. Efforts should be made in the development of immunotherapy to map specific biomarkers, which play a role in properly assigning a type of immunotherapy to the right cohort of patients, where the benefits outweigh any risks or adverse effects. The objective of this review was to provide a thorough assessment of current knowledge about the nature of the tumor process and treatment options for small cell lung cancer, with a focus on predictive biomarkers. According to the information obtained, the greatest potential, which has already been directly demonstrated in some studies, has characteristics such as tumor microenvironment composition, tumor mutation burden, and molecular subtyping of SCLC. Several other aspects appear to be promising, but more research, particularly prospective studies on a larger number of probands, is required. However, it is clear that this field of study will continue to expand, as developing a reliable method to predict immunotherapy response is a very appealing goal of current medicine and research in the field of targeted cancer therapy.PD-L1 expression; molecular subtyping; mutational burden; small cell lung cancer; tumor microenvironment

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NU21-03-00372" target="_blank" >NU21-03-00372: Small binding proteins targeting PD-1/PD-L1 immune checkpoint proteins as new diagnostic tools</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pathology & oncology research

ISSN

1532-2807

e-ISSN

1532-2807

Volume of the periodical

29

Issue of the periodical within the volume

article 1611086

Country of publishing house

CH - SWITZERLAND

Number of pages

12

Pages from-to

1-12

UT code for WoS article

000989074500001

EID of the result in the Scopus database

2-s2.0-85159662099